{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:44:56Z","timestamp":1794861896414,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSPS KAKENHI","award":["22K15693 to TT"],"award-info":[{"award-number":["22K15693 to TT"]}]},{"name":"Keio University Global Research Institute","award":["Start-up grant"],"award-info":[{"award-number":["Start-up grant"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anti-calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) are a favourable option for patients with migraine who experience distressful headache disability and fail to respond to traditional preventive treatment options. However, since CGRPmAb has been available for only 2\u00a0years in Japan, the difference between good and poor responders remains unknown. We aimed to investigate the clinical characteristics of patients with migraine in Japan who responded well to CGRPmAb based on real-world data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We analysed patients who visited Keio University Hospital, Tokyo, Japan, between the 12<jats:sup>th<\/jats:sup> of August 2021 and 31<jats:sup>st<\/jats:sup> of August 2022, and were prescribed one of three CGRPmAbs (erenumab, galcanezumab, and fremanezumab) for more than 3\u00a0months. We recorded the patients\u2019 basic migraine characteristics, such as pain quality, monthly migraine days (MMD)\/monthly headache days (MHD), and the number of prior treatment failures. We defined good responders as patients whose MMDs decreased by more than 50% after 3\u00a0months of treatment and other patients as poor responders. We compared the baseline migraine characteristics between the two groups and performed logistic regression analysis based on the items that showed statistically significant differences.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 101 patients were considered eligible for the responder analysis (galcanezumab: 57 (56%), fremanezumab: 31 (31%), and erenumab: 13 (13%)). After 3\u00a0months of treatment, 55 (54%) patients achieved\u2009\u2265\u200950% reduction in MMDs. Comparisons between\u2009\u2265\u200950% responders and non-responders revealed that age was significantly higher (<jats:italic>p<\/jats:italic>\u2009=\u20090.003), and MHD and total prior treatment failures were significantly lower (<jats:italic>p<\/jats:italic>\u2009=\u20090.027, 0.040, respectively), in responders than in non-responders. Age was a positive predictive factor, and the total number of prior treatment failures and past medical history of immuno-rheumatologic diseases were negative predictive factors of CGRPmAb responsiveness in Japanese patients with migraine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with migraine who are older, with fewer prior treatment failures and no past history of immuno-rheumatologic disease, may respond well to CGRPmAbs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01556-7","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:02:34Z","timestamp":1678320154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study"],"prefix":"10.1186","volume":"24","author":[{"given":"Keiko","family":"Ihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ishizuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"1556_CR1","first-page":"954","volume":"17","author":"GBD","year":"2016","unstructured":"GBD (2016) Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17:954\u2013976","journal-title":"Lancet Neurol"},{"key":"1556_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H (1997) Prevalence of migraine in Japan: a nationwide survey. Cephalalgia 17:15\u201322","journal-title":"Cephalalgia"},{"key":"1556_CR3","doi-asserted-by":"crossref","unstructured":"Sakai F, Ozeki A, Skljarevski V. Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial. Cephalalgia Reports. 2020;3","DOI":"10.1177\/2515816320932573"},{"key":"1556_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/head.14178","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Tatsuoka Y, Imai N, Ning X, Ishida M, Nagano K, Iba K, Kondo H et al (2021) Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61:1102\u20131111","journal-title":"Headache"},{"key":"1556_CR5","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/head.14138","volume":"61","author":"T Takeshima","year":"2021","unstructured":"Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD (2021) Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Headache 61:927\u2013935","journal-title":"Headache"},{"key":"1556_CR6","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1177\/0333102418779543","volume":"38","author":"V Skljarevski","year":"2018","unstructured":"Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38:1442\u20131454","journal-title":"Cephalalgia"},{"key":"1556_CR7","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA (2017) A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med 377:2123\u20132132","journal-title":"N Engl J Med"},{"key":"1556_CR8","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2018) Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA 319:1999\u20132008","journal-title":"JAMA"},{"key":"1556_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"U Reuter","year":"2022","unstructured":"Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, Hours-Zesiger P, Nickisch J, Sieder C, Hentschke C et al (2022) Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 42:108\u2013118","journal-title":"Cephalalgia"},{"key":"1556_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12883-022-03041-1","volume":"22","author":"T Takizawa","year":"2022","unstructured":"Takizawa T, Ohtani S, Watanabe N, Miyazaki N, Ishizuchi K, Sekiguchi K, Iba C, Shibata M, Takemura R, Hori S et al (2022) Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol 22:512","journal-title":"BMC Neurol"},{"key":"1556_CR11","doi-asserted-by":"publisher","first-page":"e2260","DOI":"10.1002\/brb3.2260","volume":"11","author":"C Baraldi","year":"2021","unstructured":"Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S (2021) Predictors of response to erenumab after 12 months of treatment. Brain Behav 11:e2260","journal-title":"Brain Behav"},{"key":"1556_CR12","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/ene.15236","volume":"29","author":"C Zecca","year":"2022","unstructured":"Zecca C, Cargnin S, Schankin C, Giannantoni NM, Viana M, Maraffi I, Riccitelli GC, Sihabdeen S, Terrazzino S, Gobbi C (2022) Clinic and genetic predictors in response to erenumab. Eur J Neurol 29:1209\u20131217","journal-title":"Eur J Neurol"},{"key":"1556_CR13","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1111\/ene.15197","volume":"29","author":"F Vernieri","year":"2022","unstructured":"Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Lovati C, Bertuzzo D et al (2022) Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. Eur J Neurol 29:1198\u20131208","journal-title":"Eur J Neurol"},{"key":"1556_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/head.14032","volume":"61","author":"P Barbanti","year":"2021","unstructured":"Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, Filippi M, Frediani F, Bono F, Grazzi L et al (2021) Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. Headache 61:363\u2013372","journal-title":"Headache"},{"key":"1556_CR15","doi-asserted-by":"publisher","first-page":"895476","DOI":"10.3389\/fneur.2022.895476","volume":"13","author":"M Nowaczewska","year":"2022","unstructured":"Nowaczewska M, Straburzy\u0144ski M, Waliszewska-Pros\u00f3\u0142 M, Meder G, Janiak-Kiszka J, Ka\u017amierczak W (2022) Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine-A Real-Life Study. Front Neurol 13:895476","journal-title":"Front Neurol"},{"key":"1556_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01213-3","volume":"22","author":"I Frattale","year":"2021","unstructured":"Frattale I, Caponnetto V, Casalena A, Assetta M, Maddestra M, Marzoli F, Affaitati G, Giamberardino MA, Viola S, Gabriele A et al (2021) Association between response to triptans and response to erenumab: real-life data. J Headache Pain 22:1","journal-title":"J Headache Pain"},{"key":"1556_CR17","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C, d\u2019Onofrio F, Albanese M, Cetta I, Di Fiore P, Zucco M, Filippi M, Bono F et al (2022) Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain 23:46","journal-title":"J Headache Pain"},{"key":"1556_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40263-021-00893-y","volume":"36","author":"LF Iannone","year":"2022","unstructured":"Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F (2022) Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score. CNS Drugs 36:191\u2013202","journal-title":"CNS Drugs"},{"key":"1556_CR19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s10072-021-05426-5","volume":"43","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V, Cainazzo MM, Torelli P, Querzani P, Pascazio A, Mascarella D, Matteo E, Quintana S et al (2022) Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci 43:1273\u20131280","journal-title":"Neurol Sci"},{"key":"1556_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s10194-021-01333-4","volume":"22","author":"S Bottiroli","year":"2021","unstructured":"Bottiroli S, De Icco R, Vaghi G, Pazzi S, Guaschino E, Allena M, Ghiotto N, Martinelli D, Tassorelli C, Sances G (2021) Psychological predictors of negative treatment outcome with Erenumab in chronic migraine: data from an open label long-term prospective study. J Headache Pain 22:114","journal-title":"J Headache Pain"},{"key":"1556_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ane.13472","volume":"144","author":"M Silvestro","year":"2021","unstructured":"Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A (2021) Refractory migraine profile in CGRP-monoclonal antibodies scenario. Acta Neurol Scand 144:325\u2013333","journal-title":"Acta Neurol Scand"},{"key":"1556_CR22","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1046\/j.1468-2982.2000.00085.x","volume":"20","author":"SJ Wang","year":"2000","unstructured":"Wang SJ, Fuh JL, Young YH, Lu SR, Shia BC (2000) Prevalence of migraine in Taipei, Taiwan: a population-based survey. Cephalalgia 20:566\u2013572","journal-title":"Cephalalgia"},{"key":"1556_CR23","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","volume":"163","author":"S Safiri","year":"2022","unstructured":"Safiri S, Pourfathi H, Eagan A, Mansournia MA, Khodayari MT, Sullman MJM, Kaufman J, Collins G, Dai H, Bragazzi NL et al (2022) Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain 163:e293\u2013e309","journal-title":"Pain"},{"key":"1556_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/head.13470","volume":"59","author":"TJ Song","year":"2019","unstructured":"Song TJ, Cho SJ, Kim WJ, Yang KI, Yun CH, Chu MK (2019) Sex Differences in Prevalence, Symptoms, Impact, and Psychiatric Comorbidities in Migraine and Probable Migraine: A Population-Based Study. Headache 59:215\u2013223","journal-title":"Headache"},{"key":"1556_CR25","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1001\/archneur.1966.00470160022003","volume":"15","author":"JW Lance","year":"1966","unstructured":"Lance JW, Anthony M (1966) Some clinical aspects of migraine. A prospective survey of 500 patients. Arch Neurol 15:356\u2013361","journal-title":"Arch Neurol"},{"key":"1556_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.bodyim.2009.11.002","volume":"7","author":"LW Kronenfeld","year":"2010","unstructured":"Kronenfeld LW, Reba-Harrelson L, Von Holle A, Reyes ML, Bulik CM (2010) Ethnic and racial differences in body size perception and satisfaction. Body Image 7:131\u2013136","journal-title":"Body Image"},{"key":"1556_CR27","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.3389\/fpsyg.2018.01741","volume":"9","author":"S Doi","year":"2018","unstructured":"Doi S, Ito M, Takebayashi Y, Muramatsu K, Horikoshi M (2018) Factorial Validity and Invariance of the 7-Item Generalized Anxiety Disorder Scale (GAD-7) Among Populations With and Without Self-Reported Psychiatric Diagnostic Status. Front Psychol 9:1741","journal-title":"Front Psychol"},{"key":"1556_CR28","unstructured":"Muramatsu K, Seiryo N, Muramatsu Y, Miyaoka H, Fuse K, Yoshine F, Hosaka M, Katagiri A, Kutumi R (2009) Validation and utility of Japanese version of the GAD-7. PANMINERVA Medica. Abstracts Book, vol 51 20th World Congress on Psychosomatic Medicine, p 79"},{"key":"1556_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.genhosppsych.2018.03.007","volume":"52","author":"K Muramatsu","year":"2018","unstructured":"Muramatsu K, Miyaoka H, Kamijima K, Muramatsu Y, Tanaka Y, Hosaka M, Miwa Y, Fuse K, Yoshimine F, Mashima I et al (2018) Performance of the Japanese version of the Patient Health Questionnaire-9 (J-PHQ-9) for depression in primary care. Gen Hosp Psychiatry 52:64\u201369","journal-title":"Gen Hosp Psychiatry"},{"key":"1556_CR30","volume-title":"R: A language and environment for statistical computing","author":"Team RC","year":"2016","unstructured":"Team RC (2016) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria"},{"key":"1556_CR31","doi-asserted-by":"publisher","first-page":"e046283","DOI":"10.1136\/bmjopen-2020-046283","volume":"11","author":"YH Kim","year":"2021","unstructured":"Kim YH, Lee JW, Kim Y, Bae JS, Kim YJ, Min C, Choi HG (2021) Bidirectional association between migraine and rheumatoid arthritis: two longitudinal follow-up studies with a national sample cohort. BMJ Open 11:e046283","journal-title":"BMJ Open"},{"key":"1556_CR32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00296-016-3604-2","volume":"37","author":"YC Wang","year":"2017","unstructured":"Wang YC, Huang YP, Wang MT, Wang HI, Pan SL (2017) Increased risk of rheumatoid arthritis in patients with migraine: a population-based, propensity score-matched cohort study. Rheumatol Int 37:273\u2013279","journal-title":"Rheumatol Int"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01556-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01556-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01556-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:02:44Z","timestamp":1678320164000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01556-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1556"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01556-7","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"assertion":[{"value":"7 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Keio University School of Medicine (approval number: 20211144). Patients were informed about this observational study via the institute\u2019s website and could opt out of the study. The need for informed consent was waived by the Ethics Committee of the Keio University School of Medicine in accordance with national regulations (Ethical Guidelines for Medical and Biological Research Involving Human Subjects). This study was performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TT serves as an adviser for Eli Lilly Japan, Otsuka, and Amgen. TT received speaker honoraria from Eli Lilly Japan, Daiichi Sankyo, Otsuka, Amgen, Kowa, Kyowa Kirin, Eisai, UCB Japan, Takeda, and Santen Pharmaceutical and research funding from Eli Lilly Japan and Tsumura outside the submitted work. JN received honoraria and research scholarships from Amgen and Daiichi Sankyo. The authors have no relevant financial or nonfinancial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}